These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31623877)

  • 1. Corrigendum to "Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis" [Cancer Lett. 380 (2016) 87-97].
    Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
    Cancer Lett; 2020 Jan; 469():526. PubMed ID: 31623877
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
    Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
    Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor kappa-B inhibition.
    Fujiwara Y; Furukawa K; Haruki K; Shimada Y; Iida T; Shiba H; Uwagawa T; Ohashi T; Yanaga K
    J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):731-9. PubMed ID: 21484229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effect by inhibition of NF-kappaB activation using nafamostat mesilate for pancreatic cancer in a mouse model.
    Furukawa K; Iida T; Shiba H; Fujiwara Y; Uwagawa T; Shimada Y; Misawa T; Ohashi T; Yanaga K
    Oncol Rep; 2010 Oct; 24(4):843-50. PubMed ID: 20811662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nafamostat mesilate suppresses NF-kappaB activation and NO overproduction in LPS-treated macrophages.
    Noguchi S; Nakatsuka M; Konishi H; Kamada Y; Chekir C; Kudo T
    Int Immunopharmacol; 2003 Sep; 3(9):1335-44. PubMed ID: 12890431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of nuclear factor kappa-B and Mdm2 enhance the antitumor effect of radiation therapy for pancreatic cancer.
    Shirai Y; Shiba H; Iwase R; Haruki K; Fujiwara Y; Furukawa K; Uwagawa T; Ohashi T; Yanaga K
    Cancer Lett; 2016 Jan; 370(2):177-84. PubMed ID: 26546875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of serine protease inhibitor nafamostat mesilate with oxaliplatin targeting NF-κB activation for pancreatic cancer.
    Gocho T; Uwagawa T; Furukawa K; Haruki K; Fujiwara Y; Iwase R; Misawa T; Ohashi T; Yanaga K
    Cancer Lett; 2013 Jun; 333(1):89-95. PubMed ID: 23348695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of nuclear factor-κB enhances the antitumor effect of tumor necrosis factor-α gene therapy for hepatocellular carcinoma in mice.
    Haruki K; Shiba H; Fujiwara Y; Furukawa K; Iwase R; Uwagawa T; Misawa T; Ohashi T; Yanaga K
    Surgery; 2013 Sep; 154(3):468-78. PubMed ID: 23972653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effect of nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells.
    Kimura T; Fuchimoto S; Iwagaki H; Hizuta A; Orita K
    J Int Med Res; 1992 Aug; 20(4):343-52. PubMed ID: 1511773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination treatment using adenovirus vector-mediated tumor necrosis factor-alpha gene transfer and a NF-κB inhibitor for pancreatic cancer in mice.
    Furukawa K; Ohashi T; Haruki K; Fujiwara Y; Iida T; Shiba H; Uwagawa T; Kobayashi H; Yanaga K
    Cancer Lett; 2011 Jul; 306(1):92-8. PubMed ID: 21482023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma.
    Yamashita Y; Ishiguro Y; Sano D; Kimura M; Fujita K; Yoshida T; Horiuchi C; Taguchi T; Matsuda H; Mikami Y; Tsukuda M
    Auris Nasus Larynx; 2007 Dec; 34(4):487-91. PubMed ID: 17337140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additional mechanisms of nafamostat mesilate-associated hyperkalaemia.
    Ookawara S; Tabei K; Sakurai T; Sakairi Y; Furuya H; Asano Y
    Eur J Clin Pharmacol; 1996; 51(2):149-51. PubMed ID: 8911880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of enteral enzymes by enteroclysis with nafamostat mesilate reduces neutrophil activation and transfusion requirements after hemorrhagic shock.
    Doucet JJ; Hoyt DB; Coimbra R; Schmid-Schönbein GW; Junger WG; Paul L W; Loomis WH; Hugli TE
    J Trauma; 2004 Mar; 56(3):501-10; discussion 510-1. PubMed ID: 15128119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.
    Han X; Wang N; Li J; Wang Y; Wang R; Chang J
    Chem Biol Interact; 2019 Jan; 297():80-84. PubMed ID: 30393114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adsorption of Nafamostat Mesilate on AN69ST Membranes: A Single-Center Retrospective and In Vitro Study.
    Nakamura Y; Hara S; Hatomoto H; Yamasaki S; Nakano T; Miyazaki M; Matsumoto N; Irie Y; Ishikura H
    Ther Apher Dial; 2017 Dec; 21(6):620-627. PubMed ID: 28960755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of nafamostat mesilate on the prevention of cerulein-induced acute pancreatitis.
    Lee JK; Ryu JK; Park JK; Lee SH; Yoon WJ; Kim YT; Jung HC; Yoon YB
    Pancreas; 2008 Apr; 36(3):255-60. PubMed ID: 18362838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nafamostat mesilate for anticoagulation in continuous renal replacement therapy.
    Hwang SD; Hyun YK; Moon SJ; Lee SC; Yoon SY
    Int J Artif Organs; 2013 Mar; 36(3):208-16. PubMed ID: 23404639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Tolerability of Nafamostat Mesilate and Heparin as Anticoagulants in Leukocytapheresis for Ulcerative Colitis: Post Hoc Analysis of a Large-Scale, Prospective, Observational Study.
    Sawada K; Ohdo M; Ino T; Nakamura T; Numata T; Shibata H; Sakou J; Kusada M; Hibi T
    Ther Apher Dial; 2016 Apr; 20(2):197-204. PubMed ID: 26771066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial for efficacy of nafamostat mesilate in preventing post-endoscopic retrograde cholangiopancreatography pancreatitis.
    Ohuchida J; Chijiiwa K; Imamura N; Nagano M; Hiyoshi M
    Pancreas; 2015 Apr; 44(3):415-21. PubMed ID: 25479585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nafamostat mesilate, as a treatment for heparin resistance, is not associated with perioperative ischemic stroke in patients undergoing cardiac surgery with cardiopulmonary bypass.
    Kikura M; Tanaka K; Hiraiwa T; Tanaka K
    J Cardiothorac Vasc Anesth; 2012 Apr; 26(2):239-44. PubMed ID: 22019206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.